UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 63

Sortiert nach

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2023-07, Vol.41 (21), p.3700-3711

2023

Volltextzugriff (PDF)

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Journal of clinical oncology, 2008-05, Vol.26 (15), p.2442-2448

2008

Volltextzugriff (PDF)

ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2013-11, Vol.31 (31), p.3926-3934

2013

Volltextzugriff (PDF)

Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab

Journal of clinical oncology, 2013-02, Vol.31 (5), p.573-583

2013

Volltextzugriff (PDF)

Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502

Journal of clinical oncology, 2013-03, Vol.31 (7), p.923-929

2013

Volltextzugriff (PDF)

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

Journal of clinical oncology, 2018-03, Vol.36 (7), p.667-673

2018

Volltextzugriff (PDF)

The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium

Journal of clinical oncology, 2023-04, Vol.41 (11), p.2076-2086

2023

Volltextzugriff (PDF)

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF V600 -Mutant Metastatic Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2023-07, Vol.41 (21), p.3700-3711

2023

Volltextzugriff (PDF)

Multiagent Chemotherapy and Deferred Radiotherapy in Infants With Malignant Brain Tumors: A Report From the Children’s Cancer Group

Journal of clinical oncology, 2005-10, Vol.23 (30), p.7621-7631

2005

Volltextzugriff (PDF)

Words Matter

Journal of clinical oncology, 2023-01, Vol.41 (3), p.706-707

2023

Volltextzugriff (PDF)

Cognitive Impairment in Older Patients With Breast Cancer Before Systemic Therapy: Is There an Interaction Between Cancer and Comorbidity?

Journal of clinical oncology, 2014-06, Vol.32 (18), p.1909-1918

2014

Volltextzugriff (PDF)

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

Journal of clinical oncology, 2014-11, Vol.32 (33), p.3697-3704

2014

Volltextzugriff (PDF)

Patterns of care and treatment outcomes in locoregional squamous cell carcinoma of the prostate

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.260-260

2021

Volltextzugriff (PDF)

Temporal trends and predictors in diagnosing pathologic node-positive prostate cancer in clinically node-negative patients

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.128-128

2021

Volltextzugriff (PDF)

Activity of EGFR inhibition in atypical (non-V600E) BRAF-mutated metastatic colorectal cancer

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.596-596

2019

Volltextzugriff (PDF)

Phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate (ADC) MYTX-011 in subjects with non-small cell lung cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS9147-TPS9147

2023

Volltextzugriff (PDF)

A window of opportunity trial for metastatic (WOO-M) pancreatic ductal adenocarcinoma (PDAC): A biomarker discovery platform

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS781-TPS781

2023

Volltextzugriff (PDF)

Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study

Journal of clinical oncology, 2021-01, Vol.39 (3), p.202-214

2021

Volltextzugriff (PDF)

Risk and protective factors for dementia in cancer survivors vary by cancer type

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e24089-e24089

2023

Volltextzugriff (PDF)

Initial results of a phase 2 pilot study of radium-223 and radiotherapy in untreated hormone-naïve men with oligometastatic prostate cancer to bone

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.156-156

2023

Volltextzugriff (PDF)

Plasma proteome landscape and impact of the circulatory proteome on clinical outcomes in metastatic prostate cancer

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.237-237

2023

Volltextzugriff (PDF)

Characterizing bone metastases and skeletal-related events in patients with well-differentiated neuroendocrine neoplasms utilizing Ga68-DOTATE PET

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.641-641

2023

Volltextzugriff (PDF)

Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8517-8517

2022

Volltextzugriff (PDF)

Shifting perceptions of alternative therapies in cancer patients during the COVID-19 pandemic: Results from the Complementary and Alternative Medicine Exposure in Oncology (CAMEO) Study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e24130-e24130

2022

Volltextzugriff (PDF)

Complementary and alternative medicine exposure in oncology (CAMEO) study: A multi-institutional cross-sectional analysis of patients receiving cancer treatment

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e18739-e18739

2022

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(63)

Sprache

Englisch
(63)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(13)
Oncology
(13)
Science & Technology
(13)
Humans
(12)
Female
(9)
Male
(9)
Aged
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Adult
(7)
Biological And Medical Sciences
(7)
Medical Sciences
(7)
Middle Aged
(7)
Original Reports
(7)
Treatment Outcome
(7)
Tumors
(6)
Aged, 80 And Over
(5)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(4)
Disease-Free Survival
(4)
Adolescent
(3)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab

Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF V600 -Mutant Metastatic Non-Small-Cell Lung Cancer

Multiagent Chemotherapy and Deferred Radiotherapy in Infants With Malignant Brain Tumors: A Report From the Children’s Cancer Group

Words Matter

Cognitive Impairment in Older Patients With Breast Cancer Before Systemic Therapy: Is There an Interaction Between Cancer and Comorbidity?

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

Patterns of care and treatment outcomes in locoregional squamous cell carcinoma of the prostate

Temporal trends and predictors in diagnosing pathologic node-positive prostate cancer in clinically node-negative patients

Activity of EGFR inhibition in atypical (non-V600E) BRAF-mutated metastatic colorectal cancer

Phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate (ADC) MYTX-011 in subjects with non-small cell lung cancer

A window of opportunity trial for metastatic (WOO-M) pancreatic ductal adenocarcinoma (PDAC): A biomarker discovery platform

Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study

Risk and protective factors for dementia in cancer survivors vary by cancer type

Initial results of a phase 2 pilot study of radium-223 and radiotherapy in untreated hormone-naïve men with oligometastatic prostate cancer to bone

Plasma proteome landscape and impact of the circulatory proteome on clinical outcomes in metastatic prostate cancer

Characterizing bone metastases and skeletal-related events in patients with well-differentiated neuroendocrine neoplasms utilizing Ga68-DOTATE PET

Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC)

Shifting perceptions of alternative therapies in cancer patients during the COVID-19 pandemic: Results from the Complementary and Alternative Medicine Exposure in Oncology (CAMEO) Study

Complementary and alternative medicine exposure in oncology (CAMEO) study: A multi-institutional cross-sectional analysis of patients receiving cancer treatment

Aktive Filter

Suchergebnisse filtern